Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Metastatic melanoma has historically had a poor prognosis; however, survival has improved with immunotherapies, such as PD-1 and CTLA-4 inhibitors, and molecular targeted therapies for BRAF-mutant tumors. The combination of nivolumab and ipilimumab is highly effective, though with increased rates of toxicity. In Italy, since January 2022, such therapeutic combination has been approved and reimbursed only for metastatic melanoma patients with brain metastases or with PD-L1 expression <1%. Methods: We conducted a real-world study in six academic centers in southern Italy and analyzed the efficacy and toxicity outcomes in 72 patients. Results: The response rate was 54% (39/72) and, after 13.6 months of median follow-up, a longer median progression-free survival [17.03 months (95% CI 4.8-18.6)] compared to the pivotal CheckMate-067 trial or to other real-world studies. Better survival correlated with objective responses (p<0.0001) and low disease burden (less than three metastatic sites) (p=0.0415). All patients achieving an objective response had tumors with high or intermediatetumor mutational burden. The rates of immune-related adverse events were similar to those reported in the literature, but there was a lower therapy discontinuation rate. This might be due to more appropriate managing of emerging immunotherapy toxicities.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study
- Date Crossref
- 16/04/2026
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Campania "Luigi Vanvitelli" pays non établi dans la noticeUniversité ou école supérieure
-
Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli pays non établi dans la noticeÉtablissement de santé
-
University of Naples Federico II Clinical Medicine and Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" pays non établi dans la noticeÉtablissement de santé
-
Azienda di Rilievo Nazionale ed Alta Specializzazione pays non établi dans la noticeÉtablissement de santé
-
European Institute of Oncology Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors pays non établi dans la noticeÉtablissement de santé
-
Department of Precision Medicine pays non établi dans la noticeInstitution
-
University of Campania “Luigi Vanvitelli” Department of Mental and Physical Health and Preventive Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Unit of Melanoma pays non établi dans la noticeInstitution
-
“Azienda Ospedaliero Universitaria (AOU) Dulbecco” Hospital Oncology Department pays non établi dans la noticeÉtablissement de santé
-
“Mons. A.R. Dimiccoli” Hospital Unit of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Medical Oncology Unit pays non établi dans la noticeInstitution
University of Campania "Luigi Vanvitelli", Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli et Clinical Medicine and Surgery — University of Naples Federico II, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.